



Press Release

2016/04/18

Company:	CYBERDYNE, INC.
Name of Representative:	Yoshiyuki Sankai, President and CEO
Code:	7779 (Mothers Section of the Tokyo Stock Exchange)
Contact:	Shinji Uga, Director and CFO (Tel. +81-29-869-9981)

Notice regarding the agreement to enter into a consigned research and development contract with AMED

As a continuation from last year, CYBERDYNE, INC (hereafter, to be referred to as “the Company”) has decided to enter into a consigned research and development agreement with Japan Agency for Medical Research and Development (hereafter, to be referred to as “AMED”) in regards to the Practical Research Project for Rare Diseases (Refer to the contents stated in “1” name of the research project as well as “2” assigned roles in the research project) for the purpose of research regarding investigator-initiated joint clinical trial by multiple facilities to acquire approval for expanding the applicable diseases in rare brain/spinal cord diseases and spinal cord injuries as set forth below.

#### 1 Name of the research project

“investigator-initiated joint clinical trial by multiple facilities for the use of (Hybrid Assistive Limb [HAL]-HN01) as a new medical device for rare brain/spinal cord diseases” (Research and Development Leader Takashi Nakajima: Niigata National Hospital, Department of Neurology, Deputy Director)

#### 2 Assigned roles in the research project

In order to assist the investigator-initiated clinical trial and to accelerate HAL-HN01's implementation in society, safety assessment based on information gathered from operation, operator training for its usage, and investigator-initiated trial will be conducted. More specifically, safety operation instruction will be conducted at each facility that will host the clinical trial and at the same time, related staff members will support those who administer the clinical trial by instructing the appropriate method of operation, and safe methods of operation will be researched. Further, if any unfavorable information regarding HAL-HN01 is found or if there are adverse events that may have been caused by HAL-HN01, the Company will gather and analyze the information, and provide appropriate measures to investigators as well as assisting doctors.

### 3 Period of consignment

From April 1, 2016 to March 31, 2017

### 4 Consigned research and development expenses (as planned)

JPY 13 Million

### 5 Future prospects

Consigned research and development expenses are planned to be calculated as non-operational income for the fiscal year ending March 31, 2017. However, it will not be determined until the screening by AMED, which will take place after the conclusion of the consigned period.